Literature DB >> 18398742

Blastic mantle cell lymphoma with a Burkitt translocation.

Kavita Reddy1, Mohammad Ansari-Lari, Bruno Dipasquale.   

Abstract

MYC gene rearrangements are observed as a genetic change in the blastoid variant of mantle cell lymphoma (MCL). We present two patients, one had 30% atypical lymphocytes with Burkitt-like morphology in the peripheral blood and the other had 30% blasts in the bone marrow. Both had a CCND1/IGH and an MYC rearrangement by cytogenetics and FISH. The immunophenotype was CD5+[one was a weak positive], CD10+, CD20+, CCND1+, >90% Ki-67 proliferation fraction and CD23 negative. The diagnosis was blastic MCL with Burkitt features. These cases, along with the reported cases, distinguish an aggressive category of a blastic MCL with a poor prognosis that probably requires Burkitt therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18398742     DOI: 10.1080/10428190701852024

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Management of Patients with MYC-Altered Lymphomas.

Authors:  Daniel J Landsburg
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

2.  An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma.

Authors:  Mauricio Zapata; Steven D Budnick; Rodolfo Bordoni; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2010-03-20

3.  CD5-negative blastoid variant mantle cell lymphoma with complex CCND1/IGH and MYC aberrations.

Authors:  Yoonmi Seok; Juwon Kim; Jong Rak Choi; Yu Ri Kim; Seo-Jin Park; Sue Jung Kim; Jaewoo Song; Kyung-A Lee
Journal:  Ann Lab Med       Date:  2011-12-20       Impact factor: 3.464

Review 4.  Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.

Authors:  Reza Setoodeh; Stuart Schwartz; Peter Papenhausen; Ling Zhang; Elizabeth M Sagatys; Lynn C Moscinski; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

5.  Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.

Authors:  Matthew J Oberley; Saurabh A Rajguru; Chong Zhang; Kyungmann Kim; Gene R Shaw; Kreg M Grindle; Brad S Kahl; Craig Kanugh; Jennifer Laffin; David T Yang
Journal:  Histopathology       Date:  2013-08-08       Impact factor: 5.087

Review 6.  The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.

Authors:  Lynh Nguyen; Peter Papenhausen; Haipeng Shao
Journal:  Genes (Basel)       Date:  2017-04-05       Impact factor: 4.096

7.  MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma.

Authors:  Lifu Wang; Guilin Tang; L Jeffrey Medeiros; Jie Xu; Wenting Huang; Cameron C Yin; Michael Wang; Preetesh Jain; Pei Lin; Shaoying Li
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

8.  Atypical rearrangement involving 3'-IGH@ and a breakpoint at least 400 Kb upstream of an intact MYC in a CLL patient with an apparently balanced t(8;14)(q24.1;q32) and negative MYC expression.

Authors:  Ina Amarillo; Peter H Bui; Sibel Kantarci; Nagesh Rao; Brit S Shackley; Rolando García; Carlos A Tirado
Journal:  Mol Cytogenet       Date:  2013-02-01       Impact factor: 2.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.